🟢 Rocket Pharmaceuticals is trading 5% up

Rocket Pharmaceuticals is trading at $2.62, up +5.44%, with no reported catalyst established as the cause of the gain.

• The October 6 announcement of up to $150 million in Hercules Capital financing provides capital for operations and the Danon disease trial; available reporting does not link it to the October 7 gain.
• On October 7, Cantor Fitzgerald reiterated an Overweight rating and $15 price target; its report followed the company’s RP-A501 update.
• Broader conditions were weak: the biotech sector was down 2.50%, while markets faced rising yields and geopolitical concerns.